(Date:11/24/2009)... The New York investment bank KTA Capital,s cli...d an AU$6.7 mil convertible note private placement...lacement was arranged by KTA Capital as Neuren,s e... New York (PRWEB) November 23, 2009 ...pital, LLC ("KTA Capital") has announced...
(Date:11/24/2009)...IS, Nov. 24 Sigma-Aldric...at the NASDAQ OMX conference on Tuesday, December ...rested parties may listen via live audio broadcast...tor.sig m a a ldrich.com/ . Users can click ...About Sigma-Aldrich: Sigma-Aldrich is a leading ...
(Date:11/24/2009)...TEO, Calif., Nov. 24 Neu... company focused on developing and commercializing...that Anthony DiTonno, President and Chief Executiv...ual Piper Jaffray Health Care Conference, to be he... in New York, New York. ,, Mr. DiTonno and Ste...
(Date:11/24/2009)...ary efficacy endpoint has been met for patients wi...cer, , QUEBEC CITY, Nov. 24 /PRNewswire-First...: AEZ) (the "Company"), a global biopharmaceutical..., today announced positive efficacy data from a Ph...njugate, AEZS-108 (formerly AN-152), in patients w...
Breaking Biology Technology:KTA Capital Arranges an AU$6.7 Million Private Placement by Neuren Pharmaceuticals 2NeurogesX to Present at Piper Jaffray Health Care Conference 2NeurogesX to Present at Piper Jaffray Health Care Conference 3AEterna Zentaris Announces Positive Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Endometrial Cancer 2AEterna Zentaris Announces Positive Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Endometrial Cancer 3AEterna Zentaris Announces Positive Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Endometrial Cancer 4...iated a Phase II study of R1507 ...ark, December 20 Genmab A/S,(OMX: GEN) announced ...e II,clinical study of R1507 for the treatment of ...y was created by Genmab under the company,s,agreem...igger a milestone,payment to Genmab of USD 500,000...
... a,drug and diagnostic discovery company, announce... to initiate a Phase 2 clinical trial of its,thera...mer,s disease. EHT,0202 is a compound, with a nove... memory and neuronal loss., This will be the firs...a multi-center, double-blind trial, in which 135 p...
...; Looks to Build Upon 2007 ...scoring its continued commitment,to advancing acce...he Avon,Foundation today announced the 2008 Avon W... in Avon Walk history, the series will expand into...mentum of a record-breaking,2007 Avon Walk season....
Other Biology Technology:Genmab A/S - R1507 Antibody to Enter Phase II Study to Treat Sarcoma 2ExonHit Gets Regulatory Approval to Initiate a Phase 2 Clinical Trial for EHT 0202 in Alzheimer's Disease 2ExonHit Gets Regulatory Approval to Initiate a Phase 2 Clinical Trial for EHT 0202 in Alzheimer's Disease 3ExonHit Gets Regulatory Approval to Initiate a Phase 2 Clinical Trial for EHT 0202 in Alzheimer's Disease 4Avon Foundation Announces 2008 Avon Walk for Breast Cancer Schedule 2Avon Foundation Announces 2008 Avon Walk for Breast Cancer Schedule 3RABBIT (BABY) COMPLEMENT LYOPHILISED from AbD Serotec
Rabbit Anti-Human ZO-1 Antibody, Unconjugated from Lab Vision
Mouse Anti-Human Myeloid Marker Monoclonal Antibody, Unconjugated, Clone BM-1 from Santa Cruz Biotechnology, Inc.
5x C'GATE STOCK STABILIZING REAGENT from AbD Serotec
Biology Products: